LXRX

Lexicon Pharmaceuticals, Inc.

LXRX · CIK 1062822 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$31M
20142024
Net Income−$200M
20142024
Operating CF−$179M
20142024
Free Cash Flow−$180M
20142024

Income Statement

MetricFY 2024↕FY 2023↕FY 2019↕FY 2018↕FY 2017↕FY 2016↕FY 2015↕FY 2014↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.1B$0.0B$0.1B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.2B$0.2B$0.1B$0.1B
SG&A Expense$0.1B$0.1B——————
Operating Income$-0.2B$-0.2B$-0.1B$-0.0B$-0.0B$-0.0B$0.1B$-0.0B
Net Income$-0.2B$-0.2B$-0.1B$-0.0B$-0.0B$-0.1B$-0.0B$-0.0B
EPS (Basic)$-0.63$-0.80$-0.62——$0.84$0.84—
EPS (Diluted)$-0.63$-0.80$-0.60——$0.76$0.76—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2019↕FY 2018↕FY 2017↕FY 2016↕FY 2015↕FY 2014↕
Total Assets$0.3B$0.2B$0.2B$0.3B$0.4B$0.5B$0.7B$0.5B
Current Assets$0.2B$0.2B$0.1B$0.2B$0.3B$0.4B$0.5B$0.4B
Cash & Equivalents$0.1B$0.0B$0.0B$0.1B$0.1B$0.0B$0.2B$0.1B
Total Liabilities$0.2B$0.1B$0.1B$0.3B$0.4B$0.3B$0.4B$0.2B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.1B$0.2B$0.1B$0.0B
Stockholders' Equity$0.1B$0.1B$0.1B$-0.0B$0.1B$0.2B$0.3B$0.3B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2019↕FY 2018↕FY 2017↕FY 2016↕FY 2015↕FY 2014↕
Operating Cash Flow$-0.2B$-0.2B$-0.1B$-0.1B$-0.2B$-0.2B$0.2B$-0.1B
Investing Cash Flow$-0.0B$-0.0B$-0.1B$0.2B$0.1B$0.0B$-0.1B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.2B$0.1B$-0.0B$0.1B$0.0B$-0.0B$0.3B
← Companies